AstraZeneca’s drug candidate baxdrostat lowered systolic blood pressure in a phase 3 clinical trial involving patients with uncontrolled or treatment-resistant hypertension. In the trial, patients who ...

Astra said its experimental drug Baxdrostat reduced the blood pressure of patients who have a treatment-resistant form of ...

The BaxHTN study met its primary endpoint, and researchers will present more data at the ESC Congress later this summer.

Brigade Enterprises Ltd., Deepak Fertilizers and Petrochemicals Corp., Sun Pharmaceutical Industries Ltd. and AstraZeneca ...

AstraZeneca (LSE:AZN) recently experienced a weekly price move of 2% amid announcements that could have supported its ...

At two doses, baxdrostat demonstrated significant reduction in mean seated systolic BP vs. placebo at 12 weeks among patients with uncontrolled or treatment-resistant hypertension, AstraZeneca ...

Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose hypertension is either uncontrolled by or resistant to existing medicines.

In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or ...

The FTSE 100 reached a record high due to optimism about potential interest rate cuts by the Bank of England and positive ...

European shares ended slightly lower on Monday, with tariff-sensitive auto stocks down after U.S. President Donald Trump's ...

The drug came to AstraZeneca through its acquisition of CinCor Pharma in 2023, with the hopes of beefing up its ...

The approval allows the company to market Imfinzi 120 mg/2.4 ml and 500 mg/10 ml in combination with gemcitabine and ...